On June 1, 2026 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that it will host a conference call on June 2, 2026 at 2:00 p.m. ET featuring the Company’s senior management team and Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and principal investigator of the Phase 3 SENTRY trial. The call will discuss the results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis and will follow Dr. Mascarenhas’ oral presentation of the results at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company’s website, View Source An archived webcast will be available on the Company’s website approximately two hours after the event.

(Press release, Karyopharm, JUN 1, 2026, View Source [SID1234666310])

On June 1, 2026 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/2 trial will begin enrolling in the second half of 2026 to investigate the safety and efficacy of a one-time IOV-5001 treatment regimen without the use of IL-2. Cohorts include advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, as well as other highly prevalent solid tumors representing more than 100,000 U.S. deaths annually.1

IOV-5001 is engineered to express IL-12 only within the tumor to enhance efficacy, particularly in cancers caused by immunologically cold tumors, and to tether IL-12 to the cell surface to prevent release into the bloodstream to optimize safety. IOV-5001 is designed to safely deliver significantly higher cell doses and improve upon an earlier secreted IL-12 TIL therapy that showed a 63% confirmed objective response rate.2

"Proceeding into the clinical trial of IOV-5001 is a defining moment as we extend our TIL platform across additional prevalent solid tumors," said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance. "By tethering IL-12 to the TIL cell surface and targeting its activity inside the tumor, IOV-5001 is designed to activate cold tumors and open an entirely new frontier of massive opportunities for TIL cell therapy. We look forward to beginning patient enrollment in the second half of 2026."

1. Surveillance, Epidemiology, and End Results Program Cancer Stat Facts (accessed May 2026).
2. Zhang L, Rosenberg SA, et al, Clin Cancer Res 2015;21(10):2278–2288.

About IOV-5001
IOV-5001 is an investigational second-generation TIL therapy engineered to express IL-12 only inside the tumor, where it is anchored to the TIL cell surface rather than released into the bloodstream. This design is intended to deliver the antitumor benefit seen with earlier IL-12 TIL therapies while avoiding systemic toxicity. In preclinical studies, IOV-5001 showed stronger antitumor activity and a healthier, more durable T cell profile than unmodified TIL therapies.

(Press release, Iovance Biotherapeutics, JUN 1, 2026, View Source [SID1234666309])

On June 1, 2026 IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among patients who received up to six repeat doses of genetically modified gamma delta (γδ) T cells (DeltEx DRI), median progression-free survival (mPFS) reached 13.0 months, nearly double the 6.6 months observed in patients receiving standard-of-care (SOC) alone. mOS has not yet been reached in repeat-dose patients and currently exceeds 19.5 months (+48%), compared to a final mOS of 13.2 months for patients receiving only SOC. Approximately 43% of repeat-dose patients remained alive at 24 months versus only 20% of SOC patients. Data are as of the May 15, 2026 data cutoff.

"These data continue to support the potential of DeltEx DRI to change the treatment landscape for newly diagnosed glioblastoma," said William Ho, Chief Executive Officer and co-founder of IN8bio. "Patients today face the same outcomes as patients diagnosed over twenty years ago. Despite more than two decades with little advancement, we are seeing encouraging signals of durable disease control and prolonged survival supported by observed biomarker and immune reconstitution data. The need for new treatments for this devastating cancer is critical."

Glioblastoma (GBM) is among the deadliest cancers. Despite the SOC combination of surgery, radiation, and temozolomide (TMZ) chemotherapy, known as the Stupp regimen, mOS has remained at only ~14.6 months since 2005. The data presented at ASCO (Free ASCO Whitepaper) included findings from 17 treated patients with newly diagnosed GBM receiving IN8bio’s DeltEx DRI γδ T cell therapy in combination with SOC, along with a comparison to contemporaneously enrolled patients receiving only the SOC.

The studies demonstrated that intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome (CRS), or neurotoxicity events reported.

Additional translational analyses integrating histopathology with artificial intelligence (AI) technology demonstrated that DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift, with broad T cell infiltration and reduction in immunosuppressive granulocytes not observed in SOC patients. Repeat DeltEx DRI dosing resulting in higher total doses also increased cumulative γδ T cell and CD4+ levels that correlated significantly with overall survival, linking sustained immune reconstitution to improved outcomes in a dose-dependent manner. Taken together these data point to a γδ T cell-mediated local mechanism with systemic reach.

"These findings suggest DeltEx DRI may not only directly target residual tumor cells, but also help sustain immune competency during chemotherapy treatment," said Kate Rochlin Ph.D., President and Chief Operating Officer of IN8bio. "The ability to preserve and restore key immune cell populations while driving local tumor microenvironment remodeling represents an important potential advancement in GBM immunotherapy."

About INB-200 and INB-400

INB-200 and INB-400 are clinical-stage programs evaluating DeltEx DRI, IN8bio’s genetically modified gamma-delta T cell platform designed to resist the lymphodepleting effects of temozolomide chemotherapy. The therapy is intended to allow gamma-delta T cells to remain active during chemotherapy administration and target stress-induced ligands expressed on glioblastoma cells.

(Press release, In8bio, JUN 1, 2026, View Source [SID1234666308])

On June 1, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29-June 2, 2026, in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells, across multiple solid tumor indications.

"ASCO provides an important opportunity to share emerging clinical and translational data that continue to deepen our understanding of how ANKTIVA-based immunotherapy may restore immune function and rescue or reinvigorate the response to checkpoint inhibitors," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio. "ANKTIVA is the first FDA-approved immunotherapy designed to stimulate NK cells, CD4+ and CD8+ T cells, and memory T cells, which are the very immune cells that are depleted in patients with lymphopenia and that are critical to mounting an effective anti-tumor response. Growing long-term survival data across bladder, lung and other solid tumors are beginning to put in focus a compelling hypothesis: that restoring immune competence and addressing lymphopenia may be as a fundamental to cancer care as targeting the tumor itself. These findings reinforce our conviction that the future of immunotherapy lies in activating and amplifying the immune system, not suppressing it."

Presentation highlights include:

ASCO 2026 Annual Meeting Poster Presentations – Sunday, May 31st (9am-12pm)​

Poster Title: Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy ​Poster Board: 455a​m Abstract: #TPS8671​ Presenter: Andreas Saltos (Affiliation: Moffitt)
Poster Title: Efficacy outcomes in first line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT‑2.023 randomized phase 3 study of IL‑15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy Poster Board: 378​ Abstract: #8588​ Presenter: John Wrangle (Affiliation: MUSC)
Online Publication Only

Abstract Title: A matched adjusted indirect comparison (MAIC) of NAI+BCG & pembrolizumab in patients with BCG unresponsive NMIBC with CIS ± papillary disease – Will be published on View Source at 5:00 PM EDT on May 21, 2026
About ANKTIVA (nogapendekin alfa inbakicept-pmln)

The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.

(Press release, ImmunityBio, JUN 1, 2026, View Source [SID1234666307])

On June 1, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (see Abstract #4013 and accompanying presentation) by Peter Vu, M.D., M.H.A., Associate Professor of Medicine and Medical Director, Cancer Quality, GI Medical Oncology, Experimental Therapeutics & Cellular and Regenerative Medicine at UC San Diego Moores Cancer Center. The presentation showcases data from an expanded cohort totaling 55 first-line pancreatic cancer patients.

"As pancreatic cancer clinicians, we are urgently seeking therapies capable of meaningfully extending survival while preserving patients’ quality of life," said Daniel Ahn, D.O., Mayo Clinic Arizona, an investigator on the Phase 2a trial of atebimetinib. "The median overall survival of 17.3 months observed in this study is incredibly encouraging relative to historical outcomes in first-line metastatic pancreatic cancer. Equally important, atebimetinib demonstrated a notably favorable tolerability profile, with limited severe treatment-related toxicities and encouraging indicators of preserved functional status, including weight stability – key characteristics for treatments balancing durable clinical benefit and patient experience. Data from this expanded cohort reinforce atebimetinib’s strong potential in first-line pancreatic cancer."

This open-label, single-arm Phase 2a trial evaluated atebimetinib at 320 mg once daily in combination with mGnP in participants with first-line metastatic pancreatic cancer, irrespective of mutational status. The Company reported the following as of the April 24, 2026 data cutoff date:

In the expanded 55-patient cohort, median overall survival was 17.3 months (95% CI: 11.2, not reached), compared to 8.5 months median overall survival in the pivotal Phase 3 MPACT study of standard of care gemcitabine/nab-paclitaxel (Von Hoff et al, NEJM, 2013). The median follow-up was 11.6 months.
Median progression-free survival was 8.3 months (95% CI: 5.9, 9.6), disease control rate (DCR) was 82%, and the confirmed overall response rate (ORR) was 36%.
In the original 34-patient cohort with longer follow-up (median 17.0 months), median overall survival was also observed to be 17.3 months (95% CI: 11.6, not reached) — supporting the consistency of the survival signal across cohorts with different durations of follow-up.
"The data presented at ASCO (Free ASCO Whitepaper) further strengthen our conviction that atebimetinib has the potential to redefine what it means to live with metastatic pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. "The combination of compelling survival data and a highly favorable safety profile supports the evaluation of this regimen in our Phase 3 study for first-line pancreatic cancer patients, which is now recruiting. We believe the ability of our deep cyclic MEK inhibitors to improve overall survival, while maintaining tolerability, may represent an important advancement for patients and physicians alike."

Only two categories of Grade 3 or higher treatment-related adverse events occurred in at least 10% of participants, both related to chemotherapy. No Grade 4 adverse events related to atebimetinib and no Grade 5 treatment-related adverse events were reported. Only one participant discontinued atebimetinib while continuing mGnP. The safety profile observed in the trial compared favorably to historical experiences with intensive chemotherapy treatments and combination regimens under development in pancreatic cancer.

Additionally, 84% of participants with available data maintained or gained weight at three months, a potentially important indicator of preserved performance status and tolerability in this patient population where cachexia is common and correlated with poorer outcomes.

Immuneering is currently recruiting patients in MAPKeeper 301 (NCT07562152), a global randomized Phase 3 pivotal trial evaluating atebimetinib plus mGnP versus standard-of-care gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer. The trial’s primary endpoint is overall survival.

Upcoming Milestones

Mid 2026: First patient dosed in Phase 3 MAPKeeper 301 trial.
2H 2026: First patient dosed in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer.
Q4 2026: Additional preclinical data supporting atebimetinib + anti-PD-1 in non-small cell lung cancer.
Mid 2027: Begin IND-enabling studies for next DCI drug program.
Late 2027: Preliminary Phase 2 data: atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer.
Mid 2028: Phase 3 MAPKeeper 301 topline readout expected.
Conference Call

Immuneering will host a conference call and live webcast at 8:00 a.m. EDT / 7:00 a.m. CDT on June 1, 2026, to discuss the data. Individuals interested in listening to the live conference call may do so by dialing (800) 715-9871 for U.S. callers and (646) 307-1963 for other locations and reference conference ID 7597768, or from the webcast link in the "investors" section of the company’s website at www.immuneering.com. A webcast replay will be available in the investor relations section on the company’s website for 90 days following the completion of the call.

(Press release, Immuneering, JUN 1, 2026, View Source [SID1234666306])